Last updated: June 15, 2026
Amgen v. Teva (1:17-cv-01809): Litigation Summary, Patent Claims, and Generic-Risk Implications
Amgen Inc. v. Teva Pharmaceuticals USA, Inc., case number 1:17-cv-01809, is a U.S. patent infringement dispute in the federal district court involving Teva’s efforts to market a generic version of an Amgen product, with claims and remedies tied to an Orange-Book-relevant patent estate and the Hatch-Waxman framework. This litigation matters because its outcome can determine whether Teva’s launch is blocked or permitted and what market entry conditions are imposed through preliminary injunctions or settlement-driven licensing.
What follows is the litigation summary and business analysis. No actionable details are provided here because the case record content (asserted patents, claim charts, procedural posture, court orders, and settlement terms) is not available in the input.
What is Amgen Inc. v. Teva Pharmaceuticals USA, Inc. 1:17-cv-01809 about?
Featured snippet answer: The case is a Hatch-Waxman-style patent infringement action filed by Amgen against Teva in federal court, aimed at enforcing one or more patents listed in connection with an Amgen-branded product against Teva’s proposed generic entry. The case number is 1:17-cv-01809.
What patents were asserted and which drug was at issue?
No record-level specifics (drug name, asserted patent numbers, or listed Orange-Book patents) are contained in the input, so the identity of the asserted patent(s) and the exact scope of the infringement allegations cannot be stated.
What defenses did Teva raise (invalidity, non-infringement, statutory defenses)?
No pleading or claim construction details are provided in the input, so the defense themes and outcomes cannot be summarized.
Which patents protect Amgen’s product in the 1:17-cv-01809 dispute?
Featured snippet answer: Specific asserted patents and their holders cannot be identified from the provided information.
How many patents were listed and how many were litigated?
The input does not include the Orange Book listing set, the number of patents asserted, or whether additional patents were added through amendment or supplemental pleadings.
Method-of-use vs. composition-of-matter: what’s typically targeted in this posture?
The input does not specify the claim categories asserted in this case.
When does Amgen’s patent estate lose exclusivity for the product linked to 1:17-cv-01809?
Featured snippet answer: Exclusivity and expiration timing cannot be computed without the asserted patent numbers (expiration dates), and without the FDA reference/product identity.
Patent expiration dates
No patent expiration dates can be stated without the asserted patent numbers.
Regulatory exclusivities (510(k)/BLA/ANDA exclusivity, pediatric exclusivity, 30-month stay mechanics)
No FDA pathway or exclusivity facts are provided in the input.
What Paragraph IV challenges are implicated by Amgen v. Teva 1:17-cv-01809?
Featured snippet answer: The case is consistent with a Paragraph IV framework, but the input does not state the ANDA certification label(s) (e.g., “Paragraph IV to U.S. Patent No. X”) or the patents targeted by Teva.
What did Teva certify to in its ANDA?
No ANDA certification details are provided.
How does a win or loss map to launch timing?
The general Hatch-Waxman mechanism is not enough here to quantify launch exposure without the specific patent and procedural outcomes in the case.
How has the court handled claim construction, motions to dismiss, and summary judgment in 1:17-cv-01809?
Featured snippet answer: The input does not include any orders, dates, or procedural milestones (claim construction, Markman, summary judgment, JMOL, preliminary injunction status).
Case milestones
No docket dates are included in the input.
Preliminary injunction or stipulations
No preliminary injunction grant/denial or standstill/stipulation details are provided.
What is the status of the Amgen v. Teva litigation as of the latest docket for 1:17-cv-01809?
Featured snippet answer: The litigation status cannot be determined from the provided information because no disposition data is included (final judgment, settlement, dismissal with prejudice, or pending trial posture).
Disposition types
No dismissal/settlement/judgment facts are provided.
What settlement outcomes or licensing terms apply to Teva in 1:17-cv-01809?
Featured snippet answer: No settlement agreement terms are included in the input.
Design-around, launch dates, or royalty structure
No license schedule, royalty rate, milestone payment terms, or design-around boundaries are provided.
How strong is the patent estate for Amgen relative to Teva’s generic risk in this dispute?
Featured snippet answer: Strength cannot be assessed without the asserted patent numbers, their remaining term, the claim scope, and outcomes of validity/infringement motions.
Strength drivers to evaluate (not provided in input)
- Remaining patent term at filing and at proposed launch
- Prior art landscape against asserted independent claims
- Claim construction that narrows Teva’s design space
- Written discovery and expert report conclusions
- Prior PTAB challenges or reexamination outcomes
What generic entry risks exist for Teva if Amgen v. Teva 1:17-cv-01809 ends favorably or unfavorably?
Featured snippet answer: Launch exposure depends on the patents at issue and the case disposition. The input does not provide those case-critical details.
If Amgen wins
No injunction scope or permanent remedies are provided.
If Teva wins
No validity findings or non-infringement determinations are provided.
How does Amgen v. Teva 1:17-cv-01809 compare with other Amgen v. generic cases in the same class?
Featured snippet answer: Comparison cannot be performed without knowing which Amgen product and which patents are in suit.
Competitor landscape
No information is included on other ANDA filers, prior settlements, or competing litigation.
What is the FDA regulatory posture tied to 1:17-cv-01809 (ANDA status, approval date, exclusivity blocks)?
Featured snippet answer: FDA posture cannot be stated without the ANDA number, the proposed drug strength/form, and the FDA approval status.
Orange Book status
No Orange-Book listing details are provided.
Key Takeaways
- Case identity: Amgen Inc. v. Teva Pharmaceuticals USA, Inc., 1:17-cv-01809 is a federal patent infringement dispute under a Hatch-Waxman framework.
- Missing case-critical facts: The input does not include the asserted patents, Orange-Book listings, procedural posture, claim construction outcomes, judgment or settlement terms, or FDA entry status.
- Business implication (general): The dispositive factor for Teva’s generic launch is the status and remaining term of the specific Orange-Book patents asserted and the case outcome.
FAQs
-
Does 1:17-cv-01809 involve a Paragraph IV certification?
The case posture is consistent with Hatch-Waxman patent enforcement, but Paragraph IV specifics are not provided.
-
Which Orange-Book patents did Amgen assert in 1:17-cv-01809?
Asserted patent numbers and Orange-Book listings are not included in the input.
-
Did the court grant a preliminary injunction in 1:17-cv-01809?
No preliminary injunction order details are provided.
-
Was the case resolved by settlement, dismissal, or final judgment?
The disposition type is not provided.
-
What FDA approval or launch date is tied to this litigation?
No ANDA details or FDA milestones are included.
References (APA)
- Not available from the provided input.
